【1 月 13 日,中银国际发布研究报告称】和黄医药近期宣布以 6.08 亿美元出售其在上海和黄药业 45%股份,市盈率为 15 倍。出售所得将用于加速全球创新及开发其专有的下一代抗体靶向偶联药物 ATTC 平台,公司预计 2025 年下半年启动 ATTC 候选药物临床试验。赛沃替尼联用奥西替尼的 NDA 申请已被 CDE 受理并纳入优先审查,预计今年首季在美国提交 NDA 申请。向 CDE 提交...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.